Azidothymidine (Zidovudine, AZT) is part of the standard care of treatment for acquired immunodeficiency syndrome since many years. A great number of studies on the genotoxic potential of AZT have been published, but no comprehensive hypothesis yet explains all observations. We investigated a multitude of genotoxic endpoints, both in vitro and in vivo, with the goal to complete the picture. The mutagenic potential of AZT in bacteria was found to be restricted to strains with an "ochre" target sequence and could be abrogated both by thymidine supplementation and rat liver S9 mix. Single-strand breaks in mammalian cells were detected in the comet assay after short-term treatment (3 h) with AZT, which did not induce micronuclei. The latter were mainly seen after prolonged exposure (24 and 48 h) and are probably not directly related to AZT incorporation into DNA. Our data demonstrate that short-term exposure to low AZT concentrations does not induce biologically relevant micronucleation. Only treatment with high concentrations of AZT for prolonged time periods manifests in substantial micronucleus induction. Furthermore, we found that high concentrations of thymidine have no effect in the comet assay but increase micronucleus frequency in a manner very similar to AZT. These results lead us to the following hypothesis: AZT is triphosphorylated and then incorporated into DNA strands, leading to mutations and cytotoxicity. Cellular attempts to repair these DNA lesions as well as stalled replication forks due to chain termination are detectable with the comet assay. Increased micronucleus frequency is likely related to nucleotide pool imbalance.
3′-Azido-3′-deoxythymidine (AZT, Zidovudine) was introduced in 1987 as the first nucleoside reverse transcriptase inhibitor (NRTI) and remains a mainstay in the therapy of acquired immunodeficiency syndrome until today. AZT is a thymidine analog with an azido moiety at the 3′ position. It is used as a part of the highly active antiretroviral therapy regime and for the prevention of vertical human immunodeficiency virus transmission during childbirth. AZT's pharmacological mode of action is mainly based on inhibition of the viral enzyme reverse transcriptase. Following oral application, it is well absorbed (Sommadossi et al., 1989) and converted by a series of phosphorylation steps to azidothymidine-triphosphate (AZTTP), which in turn is incorporated into viral and-to a much lesser degree-host-DNA (Furman et al., 1986; Meng et al., 2000b; Sommadossi et al., 1989; St Clair et al., 1987) . AZTTP is generated only to a minor extent (~1%), whereas the majority of AZT is excreted directly or further metabolized to glucuronic acid conjugates and/or reduced to 3′-amino-3′-deoxythymidine (AMT) (Cretton et al., 1991; Veal and Back, 1995) .
The general genotoxic potential of NRTI is well known. For AZT in particular, a profound clastogenic effect has been observed in several test systems in vitro, but evidence for induction of gene mutations is less convincing and restricted to high concentrations or extended treatment periods.
Increased gene mutation frequencies were observed in several studies: in TK6 cells (tk and HPRT loci) following treatment for up to 6 days with 300µM AZT (corresponding to around 80 µg/ml) (Meng et al., 2000b) , in L5178Y cells (tk locus) (Ayers et al., 1996) , and HepG2 cells (HPRT locus) at approximately 600 µg/ml but not in CHO cells (HPRT locus) (Grdina et al., 1992) . APRT-gene mutations were induced in AZH1 cells following 3-day treatment (Meng et al., 2000a) . Responses generally correlate with cumulative dose of AZT and the induced mutations are predominantly deletions, resulting mainly in loss of heterozygosity (Sussman et al., 1999; Torres et al., 2007; Wang et al., 2007) .
Clastogenicity, detected as chromosomal aberrations and micronuclei, has been observed in several test systems at concentrations above 100 and 500 µg/ml, respectively, whereas primary DNA damage increased comet tail intensity starting at concentrations of 208 µg/ml and higher (Agarwal and Olivero, 1997; Escobar et al., 2007; González Cid and Larripa, 1994; Phillips et al., 1991; Wutzler and Thust, 2001) .
Additional observations related to genotoxicity biomarkers (nuclear bud formation, cell cycle delay, telomeric attrition, toxicological sciences 135(2), 317-327 2013 doi:10.1093/toxsci/kft149 Advance Access publication June 28, 2013 nucleotide pool imbalances, impairment of DNA-repair fidelity, 8-oxo-dG formation, aneuploidogenicity, centrosomal amplification, SOS-response induction, etc.) predominantly occurred after treatment for prolonged periods (i.e., several days) or with high doses (Borojerdi et al., 2009; de la Asuncion et al., 2004; Hayakawa et al., 1991; Mamber et al., 1990; Olivero, 2008; Olivero et al., 2004 Olivero et al., , 2009 Olivero et al., , 2010 . The data on biomarkers are reviewed in IARC (2000), Kunz et al. (1994a) , and Olivero (2007) .
The relevance of these findings for in vivo genotoxicity and, even more important, carcinogenicity is not yet fully understood.
Our aim in the experiments described below was to more comprehensively assess the genotoxic potential of AZT in vitro and additionally find modulating factors eventually bridging toward the in vivo relevance of our results. Gene mutations, DNA breakage, clastogenicity, and aneugenicity were analyzed and experimental conditions varied to investigate the mode of action. The experiments performed were conducted in parallel to a multiple-endpoint in vivo study in rats also covering gene mutations (Pig-a), clastogenicity (MNT), and DNA breakage (comet) endpoints (Guérard et al., 2013) , in which genotoxic effects of AZT in vivo are discussed.
MATerIALS AND MeThODS

Chemicals
Azidothymidine (AZT, CAS 30516-87-1) was purchased from Lianhe Chemical Technology Co., Ltd (Zhejiang, China), with a purity of 98.6%, and dissolved either in water (Ames assay) or dimethyl sulfoxide (DMSO) (comet assay, micronucleus test). The S9 liver homogenate was obtained from phenobarbital/5,6-benzoflavone-induced rat liver (Moltox). Thymidine (Acros organics, CAS 50-89-5) was dissolved together with AZT in water (Ames assay) or DMSO (comet assay, micronucleus test).
Mutagenicity test
The plate incorporation protocol of the Ames test according to Maron and Ames was used (Maron and Ames, 1983) . Variations of the standard assay conditions are described in Results section. The mutagenic potential of AZT was assessed by using the standard battery of Salmonella tester strains (TA97, TA98, TA100, TA102, and TA1535) as well as TA104, TA2638, Escherichia coli WP2, and WP2uvrA. The S9 mixture was freshly prepared according to Ames et al. (1975) and stored on ice during the experiment. The experiments were performed with standard S9 mix as well as cofactor-depleted or heatinactivated S9 mix. The final S9 concentration in the soft agar was around 2%. Colonies were counted with the aid of a SORCERER automatic image analysis system (Perceptive Instruments, Haverhill, Suffolk, United Kingdom). Toxicity was determined by a reduction of background growth and/or reduction of mutant colony numbers.
Comet Assay and Micronucleus Test
Treatment of the cultured cells. AZT was dissolved in DMSO and further diluted in RPMI/10% horse serum (HS). L5178Y mouse lymphoma cells (ATCC) were incubated with different concentrations of AZT for 3-48 h in the absence of metabolic activation (−S9 mix) and for 3 h in the presence of metabolic activation (+ S9 mix) at 37°C, 5% CO 2 , and 95% relative humidity (RH) using 6-well plates. Cells were incubated with AZT alone or together with thymidine.
Following the respective treatment time, cells were centrifuged, washed, and resuspended in RPMI/10% HS.
In order to study the time course of the DNA damage and repair in the comet assay, samples of the cell suspension were taken at different time points during the incubation with AZT (0.5, 1, 2, and 3 h) and during the treatment free period following washing. After 3 h, cells were washed free of AZT, resuspended in RPMI/10% HS, and incubated at 37°C, 5% CO 2 , and 95% RH. Again, samples were taken once per hour up to 8 h after start of the treatment, corresponding to 5 h of recovery and the comet assay was performed. An additional sample was taken at 24 h (21-h recovery, respectively).
For the micronucleus test, four different treatment and recovery time schedules were investigated: 3-h treatment + 21-h recovery (± S9), 24-h treatment without recovery, 24-h treatment + 24-h recovery, and 48-h treatment without recovery.
Comet assay analysis. For the comet assay, the protocol recommendations given by Tice et al. (2000) were generally followed. Cell suspension was mixed with low melting agarose at 37°C and layered onto agarose-precovered slides. After lysis of cells (at least 1 h, pH 10) and an alkaline unwinding step (20 min, pH > 13), electrophoresis was performed at around 1 V/cm for 40 min. Slides were neutralized, fixed in EtOH, and stored dry until analyzed. In parallel, cytotoxicity was assessed by using the Alamar Blue test (Biosource, 24-well plates). For the Alamar Blue assay, cells were incubated with 10% of the dye for around 1 h and fluorescence of reduced Alamar Blue (resorufin) was measured in duplicate wells. To calculate relative viability, background fluorescence was subtracted and values were related to solvent controls.
Following staining with propidium iodide (5 µg/ml in Vectashield), examination of the comet assay slides was performed in a coded manner with the Metafer/Relosys 4 System (Metasystems, Germany) coupled to a Zeiss microscope (×20 objective) by measuring 150 comets. All images of comet cells were manually checked and artifacts (such as cell fragments) were rejected. The median percentage tail intensity of the first 100 comets per slide was computed and used to calculate the mean of two replicate slides.
Micronucleus analysis.
The micronucleus test was performed according to OECD guideline no. 487 (OECD, 2010) and as described by Kirchner and Zeller (2010) with the exception of staining and slide evaluation: propidium iodide (0.25 µg/ml) and 4′-6-diamidino-2-phenylindole (0.25 µg/ml) were applied together with ProLong Gold Antifade to the slides to visualize both plasma membrane envelope and nuclear DNA without phase contrast optics. Fluorescence images of 1000 cells per concentration were processed automatically with a proprietary classificator using a MetaSystems Metafer/Relosys 4 image analysis system coupled to a motorized Zeiss fluorescence microscope. Cell images were manually checked for image recognition artifacts prior to slide decoding.
reSuLTS
Salmonella typhimurium Reversion Assay (Ames test)
AZT was evaluated in the plate incorporation assay with the standard battery of tester strains (TA1535, TA97, TA98, TA100, and TA102) at concentrations of 0.1-10 µg/plate both in the absence and presence of metabolic activation. Toxicity, apparent as reduction in background revertant colony numbers, was visible for all strains at concentrations ≥3.16 µg/plate. A clear increase of the number of revertant colonies was only observed in strain TA102, solely in the absence of metabolic activation (Fig. 1 , data with S9 not shown). Thus, we decided to investigate bacterial mutagenicity of AZT in more detail and evaluated the following set of tester strains.
(1) TA2638 (excision repair proficient) and TA104 (excision repair deficient), having the same hisG428 target sequence as TA102 but being located on the bacterial chromosome instead of a plasmid and (2) the E. coli strains WP2 (excision repair proficient) and WP2uvrA (excision repair deficient) with a different AT sequence compared with TA102 at the site of mutation (Levin et al., 1984) . Although a more than threefold increase of revertant counts over controls was observed in TA102, a two-and threefold increase over concurrent solvent controls was evident in TA104 and WP2uvrA, respectively, whereas TA2638 showed only a marginal response of 1.5-fold and WP2 revertant colony counts did not increase to a relevant extent (Fig. 2) . As for the standard strains, toxic effects were observed in all AT strains (TA102, TA104, TA2638, E. coli) at concentrations ≥3.16 µg/plate.
Because AZT competes with its natural homolog thymidine regarding incorporation into DNA, it was of interest to investigate the effect of excessive thymidine in TA102. Addition of ≥200 µg/ plate thymidine completely suppressed the mutagenic effect of AZT (Fig. 3) . There was some indication that the cytotoxicity of AZT (as indicated by a decrease in revertant colony counts and thinning/absence of bacterial background lawn) was also slightly reduced with increasing thymidine concentrations, but the effect was marginal compared with the decrease of mutagenicity.
To our knowledge, no data on metabolism of AZT in bacteria have been published in the open literature. Because liver S9 mix completely abolished the mutagenic effect of AZT in strain TA102, an experiment with S9 mix without the addition of the cofactor NADP and with heat-inactivated S9 (60°C for 60 min) was performed. Although the NADP depleted S9 mix was still capable to abolish the mutagenic effect, heat-inactivated S9 did not suppress the mutagenic effect of AZT (Fig. 4) . S9 mix did not lead to a clear reduction of AZT-mediated cytotoxicity as measured by reduction of bacterial background lawn or decrease in revertant colony counts.
In Vitro Micronucleus Assay
Four different treatment and recovery time schedules have been investigated: 3-h treatment + 21-h recovery, 24-h treatment without recovery, 24-h treatment + 24-h recovery, and 48-h treatment without recovery. Cytotoxicity/cytostasis calculated as relative cell count (RCC) remained below 50% of controls in all experiments except for the highest concentration of the 48 h treatment where cell counts decreased to 24% of controls after exposure to 1000 µg/ml AZT. With this exception, toxicity had probably no relevant effect on micronucleus frequency.
Following exposure to AZT, a dose-related increase of micronucleated L5178Y cells exceeding the 95% upper limit of the historical control range of our laboratory (0.3%) was observed under all conditions. Short-term treatment followed by a recovery period (3 + 21 h) mildly induced micronucleated cells at a concentration of 2000 µg/ml (up to 0.7%), whereas maximum 2.5% micronuclei containing cells were caused by 1000 µg/ml for 24 h. Micronucleus induction increased steeply with AZT treatment duration and reached 8.3% after 48 h exposure to 1000 µg/ml. A substance-free recovery period of 24 h following treatment for the same period had practically no effect on the fraction of micronucleated cells (Fig. 5) .
Cotreatment of AZT with thymidine did not abrogate the clastogenic effect of AZT as might be expected from the strong diminution of mutagenicity observed in the bacterial experiments (Fig. 3) . In contrast, thymidine alone increased micronucleus frequency similar to AZT after 48 h (Fig. 6) . By plotting micronuclear frequency against the sum of AZT and thymidine concentrations, their effect appears to be additive in a very linear manner (Fig. 7) . However, strong cytotoxicity interferes with the micronucleus response at combined concentrations >2000 µg/ml and results at such concentrations should be interpreted with care. Even without AZT, thymidine did suppress cellular proliferation (Fig. 6) .
Comet Assay
Two types of studies have been performed: the dose-response relation was investigated with a single fixed treatment time of . 3 . Salmonella reversion assay: revertant colony counts in strain TA102 following AZT treatment and coincubation with thymidine in the absence of metabolic activation. Each datapoint represents the arithmetic mean of three plates. Thinning or absence of bacterial background lawn was observed at 10 and 100 µg AZT/plate without thymidine, at 100 µg/plate with 200 µg/plate thymidine coincubation, and no effects on background growth were noticed at the two highest thymidine concentrations.
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Following 3-h AZT treatment, comet tail intensity was increased up to approximately 40%, indicating very prominent induction of DNA breakage following short treatments. Without S9 mix, absolute tail intensities were slightly higher than with S9 both in solvent and AZT-treated groups, but the slopes of both dose-response curves are nearly identical, indicating no substantial influence of metabolic activation on primary DNA damage elicited by AZT (Fig. 8) . Thymidine addition did not modulate the genotoxic effects of AZT measured with the comet assay to a relevant extent and did, in contrast to the above-described micronucleus assay, not induce DNA damage itself (data not shown).
FIg. 4.
Salmonella reversion assay: revertant colony counts in strain TA102 with modifications in the rat liver S9 activation process. Heat inactivation denatures the enzymes, whereas omission of the cofactor NADP inhibits its catalytic activity. Each datapoint represents the arithmetic mean of three plates. In the kinetics experiment, a rapid increase during the 3-h treatment period was observed following treatment with concentrations of 500 and 1000 µg/ml AZT, whereas results with 250 µg/ml only weakly surpassed control levels. After removal of AZT from the culture medium, an apparent plateau phase of 3-5 h and finally a slow decrease of comet tail intensity values down to background levels were observed at 500 µg/ml AZT. Damage levels in cells treated with 1000 µg/ml were still clearly higher than control after 21-h recovery, indicating a less efficient DNA repair (Fig. 9) .
Cytotoxicity, measured as a decrease in Alamar Blue reduction, was observed in all experiments. The strongest reduction of cell viability (to approximately 70% of controls) occurred after treatment with 1000 µg/ml AZT for 24 h and 2000 µg/ ml for 3 h. Metabolic activation with S9 did not modulate the decrease in viability to a relevant extent. Overall, no viability values below 65% (calculated as percentage of solvent controls Alamar Blue reduction) have been recorded following AZT treatment. Coincubation with thymidine did not substantially contribute to the cytotoxicity.
DISCuSSION
Bacterial Test Systems
In our experiments, AZT was mutagenic in strain TA102 without S9 mix, but not in strains TA97, TA98, TA100, and TA1535. This is in line with results of three published studies: two of them are indicating a lack of mutagenic potential of AZT but the authors did not use strains with A-T-base pair sequences as mutational targets (Ayers et al., 1996; Ballardin et al., 2005) . The third study (NIH, 1991) points toward a weak mutagenic potential in S. typhimurium strain TA102 in the absence of metabolic activation.
To explain the TA102 specificity observed in our experiments and the National Toxicology Program (NTP) study, some characteristics of this strain have to be emphasized: it differs from the other commonly used strains (TA97, 98, 100, and 1535) in several aspects: (1) its mutational target (hisG428) contains a TAA ("ochre") sequence (Hartman et al., 1986) , (2) the site is located on a multicopy plasmid and not part of the chromosomal DNA (Gocke and Albertini, 1989; Levin et al., 1984) , and (3) it is excision repair proficient (Maron and Ames, 1983 ). Because the above-mentioned "standard" strains contain only G or C and not T at their mutational target sites, it is tempting to implicate this with the TA102 specificity of AZT. We, therefore, included the adjunct tester strains TA2638 and TA104 as well as E. coli strains, which also contain a TAA target sequence. There is some minor modulation of the effect by repair capacity and location of the target site (plasmidal vs. chromosomal), but overall the positive trends observed in the additionally tested strains containing A-T base pairs at the mutational site indicate that this sequence appears to be the decisive factor (Fig. 2) .
Incorporation of AZT should not lead to mutations through mispairing because the pyrimidine moiety of AZT is unchanged compared with thymidine. Hence point or frameshift mutations should arise through different mechanisms. It has been described that TA102 can be reverted by small deletions (3 or 6 bp in length) covering the stop codon (Levin et al., 1984) . Incorporated AZT causing chain termination has to be removed, for example exonucleolytically (Vazquez-Padua et al., 1990) , to allow continuation of the DNA replication (and/or ligation of backbone bonds). It is suggested that during this process, small in-frame deletions could arise, which restore the enzymatic function of the hisG gene product by deleting the stop signal.
The observation that excess thymidine suppresses the mutagenic activity of AZT is easily accommodated by this hypothesis as competing thymidine will reduce the likelihood of AZT insertion. If incorporation of AZT into DNA would be the basis of its toxicity, it appears that thymidine, competing with AZT for incorporation, should reduce mutagenicity to the same extent as toxicity. Surprisingly, the addition of thymidine did only marginally suppress the cytotoxic activity of AZT. It seems plausible that because the number of (plasmidal) hisG-reversion target sites is orders of magnitude lower than the number of (chromosomal) target sites for replication fork stalling leading to cytotoxicity, the latter are probably less influenceable by thymidine supplementation. Another possible explanation is conceivable if polymerase inhibition by AZT is assumed to be irreversible as this would also preclude an impact of thymidine on cytotoxicity.
We were rather surprised by the reduction of mutagenic potency toward TA102 exerted by rat liver S9 mix because it is mainly used to simulate oxidative metabolism, which is unreasonable, given the chemical structure of AZT. Although S9 contains many enzymes capable of conjugating xenobiotics, these phase II reactions are usually not catalyzed by standard S9 mix because the necessary cofactors are lacking (Oesch et al., 1988) . We initially speculated that protein adsorption plays a role but this has proven not to be the case because heat inactivation of S9 mix did completely abolish its protective effect. In contrast, omitting NADP had no influence on the impact of S9 mix on AZT mutagenicity in TA102. Hence, an enzymatic pathway that does not rely on NADP as cofactor must be involved. We suppose that cytochrome P450 reductase is playing a key role. The reductive formation of AMT, which is a known metabolite of AZT in humans and in vitro (Eagling et al., 1994) , was demonstrated to take place in vitro even in the absence of NADPH (Cretton and Sommadossi, 1993) and it seems plausible that AMT is quantitatively formed by S9 and at same time possesses a cytotoxic (Cretton et al., 1991) but no mutagenic potential. Because toxicity limited the maximum dose to less than 10 µg/ml AZT in the Ames assays, a complete conversion of the parent compound to a less mutagenic but equally cytotoxic metabolite seems possible.
Mammalian Test Systems
We observed a dose-related increase of primary DNA damage in the comet assay following 3-h incubation with AZT without a biologically relevant influence of metabolic activation on the slopes of the dose-response curves (Fig. 8) . In order to investigate the kinetics of DNA repair in mammalian cells, we performed a time-course experiment with the comet assay (Fig. 9) . DNA damage following treatment with 1000 µg/ml AZT plateaued for approximately 3-5 h and gradually decreased thereafter. The DNA-damaging effect was far weaker at a lower AZT concentration (500 µg/ml) and undetectable at 250 µg/ml. Both stalled replication forks due to chain termination and DNA-repair processes are expected to lead to increased comet tail intensity. The latter was recognized as being the predominant factor for comet responses in human cells exposed to several potent genotoxins that did, however, not belong to the chemical class of nucleoside analogs (Speit and Hartmann, 1995) . Kaina and others report on processes that lead from stalled replication forks to chromosomal aberrations (Bourn et al., 2009; Cox, 2001; Kaina, 1998; Sutera and Lovett, 2006) , a mechanism well conceivable with AZT. Furthermore, 
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AZT is known to lead to nucleotide pool imbalances, which are impairing DNA-repair fidelity (Kunz et al., 1994b) .
It seems plausible that cellular repair attempts are doomed in an environment rich in AZT, causing contamination of free nucleotide pools with this analog, a process that has been described for other genotoxins (Arecco et al., 1988; Snow and Mitra, 1988) . Mismatch repair (MMR) probably is most susceptible to this "pool contamination" because relatively large patches of DNA (1000 bp and more) are excised and repolymerized during MMR (Armstrong and Galloway, 1997; Galloway et al., 1995; Grilley et al., 1990; Hsieh, 2001; Schofield and Hsieh, 2003) . The freshly repaired DNA might therefore again contain AZT, leading to a potentiation of the DNA damage in cells by futile removal-insertion cycles.
Our comet results support those published data with AZT (Escobar et al., 2007; Slamenova et al., 2006) and point toward AZT incorporation and subsequent excision repair (or repair attempts) as being the main drivers of single-strand breakage.
Coincubation with excess thymidine competitively suppressed mutagenicity of AZT in S. typhimurium TA102 in our experiments, whereas we did not observe a relevant suppression of clastogenicity in mammalian cells. Their indifference might be based on the reported impossibility to modify cellular nucleotide pool size through extracellular thymidine supplementation (Darnowski and Goulette, 1994) . On the other hand, a much lesser thymidine excess over AZT could be employed in our experiments with mammalian cells compared with the bacterial test system.
Long-term treatment with AZT induced micronuclei, whereas a 3-h treatment only led to a strong response in the comet assay and micronucleation was rather weak. A prolonged recovery time of 24 h was used in one micronucleus experiment to account for a possible cell cycle delay but no substantial influence of recovery time was detectable (Fig. 5) . This observation is in line with data reported in González Cid and Larripa (1994) , indicating that effects on the cell cycle mainly arise at very high AZT concentrations. Because the DNA damage induced through incorporation was measurable quite instantly in our comet experiments, micronucleus induction following long-term treatment most likely is based on a different mode of action. This is corroborated by the very similar micronuclear response to thymidine treatment, which contrarily is not causing a comet response. It is, therefore, concluded that the predominant mechanism of micronucleus induction through AZT is the same as for thymidine (Anderson et al., 1981) : nucleotide pool imbalance. Because thymidine alone does also induce micronuclei (Fig. 7) , it is obvious that externally added thymidine will not be able to abrogate the genotoxic response like it does in bacteria. Moreover, the excess ratio thymidine over AZT is much lower in our experiments with mammalian cells and this probably explains why the genotoxic effect of AZT observed in the comet assay was not mitigated by thymidine.
SuMMArY
Our findings show that although AZT is very cytotoxic toward bacteria, its mutagenic effect detectable in the Ames test in AT strains (e.g., TA102) is relatively weak. AZT causes both primary DNA damage (comet) and clastogenicity in mammalian cells. Coincubation with thymidine suppresses only bacterial mutagenicity without affecting the mammalian cell response to AZT. Rather, thymidine induces micronuclei in a similar pattern as AZT.
These results suggest that the DNA-repair systems of mammalian cells can convert initial DNA lesions induced by AZT into large deletions and aberrations detectable with standard genotoxicity test systems. It appears that the genotoxic potential of AZT in mammalian cells is mainly related to nucleotide pool imbalance effects at high concentrations.
Because it is difficult (or impossible) to extrapolate from these in vitro findings to doses of clinical relevance, their significance for human risk assessment can only be judged in conjunction with in vivo data. Such in vivo experiments were performed by our group in parallel to this work and the results are reported and discussed in (Guérard et al., 2013) .
